Blogs & Insights
Explore the latest in biotech and research, crafted to inspire your next breakthrough.
New Updates
How to Choose the Right Alzheimer's Disease Research Model
View Details
Three Novartis Clinical Setbacks in Eight Days: What CAR-T, Pelacarsen, and Del-Desiran Reveal About Translational Risk
View Details
Beyond Topo I: Why Genentech’s $1B Deal with DualityBio Signals the Next Phase of ADC Development
View Details
Is INHBE Only Half of the Activin Story?
View Details
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Filter By
All Topics
Animal Science and Quality
Autoimmunity & Inflammation
Cardiovascular Research
Cell & Gene Therapy
Genetic Disorders and Genomics
HUGO-Ab
Immunology
Infectious Diseases & Vaccines
Metabolism & Obesity
Neuroscience
Oncology
Ophthalmology
Precision Medicine & Biomarkers
Rare Diseases
Regenerative Biology
Milestones & Highlights
Filter By
Neuroscience
How to Choose the Right Alzheimer's Disease Research Model
View Details
Animal Science and Quality
Three Novartis Clinical Setbacks in Eight Days: What CAR-T, Pelacarsen, and Del-Desiran Reveal About Translational Risk
View Details
HUGO-Ab
Beyond Topo I: Why Genentech’s $1B Deal with DualityBio Signals the Next Phase of ADC Development
View Details
Metabolism & Obesity
Is INHBE Only Half of the Activin Story?
View Details
Oncology
Enhertu’s First-Line Phase III Win in HER2-Mutant NSCLC: Are ADCs Moving into Precision Frontline Therapy?
View Details
HUGO-Ab
Breaking Immune Tolerance to ACVR2A: A Fully Human Antibody Strategy for Muscle and Metabolic Disease
View Details
Autoimmunity & Inflammation
Sonelokimab Phase III Win Puts the IL-17A/F Nanobody Strategy in Focus
View Details
Autoimmunity & Inflammation
Beyond Type 2 Inflammation: The Next Decade of IL-4Rα Therapeutics and the Humanized Mouse Model Breakthrough
View Details
Immunology
Argenx's $2.2B Forte Deal Puts CD122 in the Autoimmune Spotlight
View Details
1
2
3
4
5
6
...
20
21
More